CPI-444 inhibits tumors alone and in combo regimens
BURLINGAME, Calif.—Preclinical data for Corvus Pharmaceuticals Inc.’s CPI-444 was recently published in Cancer Immunology Research, detailing the compound’s dose-dependent antitumor responses both as a monotherapy and in combination with anti-PD-1, anti-PD-L1 and anti-CTLA-4 therapies. CPI-444 was found to be a selective, potent inhibitor of the adenosine A2A receptor and demonstrated dose-dependent inhibition of tumor growth as a monotherapy. The compound proved synergistic with all other tested therapies, eliminating tumors in up to 90 percent of treated mice in addition to restoring immune responses in mice that had developed resistance to anti-PD-L1 or anti-CTLA-4 monotherapy. CPI-444 inhibited tumor growth and led to long-term antitumor immune memory both alone and in combination with other tested therapies.